Enovis (NYSE:ENOV) Raised to “Strong-Buy” at UBS Group

Enovis (NYSE:ENOV) was upgraded by stock analysts at UBS Group to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Zacks Research lowered Enovis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 30th. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a report on Monday, July 6th. William Blair started coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Finally, Wells Fargo & Company cut their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and an average target price of $41.86.

Enovis Stock Up 2.2%

ENOV stock opened at $30.18 on Tuesday. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The firm has a 50-day moving average of $23.86 and a two-hundred day moving average of $23.78. Enovis has a 12 month low of $19.14 and a 12 month high of $34.28. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -1.52 and a beta of 1.39.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. During the same period in the prior year, the business earned $0.81 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts forecast that Enovis will post 3.12 earnings per share for the current fiscal year.

Insider Transactions at Enovis

In other Enovis news, insider Oliver Engert bought 1,200 shares of Enovis stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders acquired a total of 4,200 shares of company stock worth $92,084 over the last ninety days. 2.90% of the stock is owned by company insiders.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Arax Advisory Partners purchased a new stake in Enovis in the 4th quarter valued at about $29,000. EverSource Wealth Advisors LLC boosted its stake in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the period. Danske Bank A S acquired a new stake in shares of Enovis during the third quarter valued at about $64,000. iSAM Funds UK Ltd acquired a new stake in shares of Enovis during the third quarter valued at about $80,000. Finally, Brown Brothers Harriman & Co. purchased a new stake in shares of Enovis in the 3rd quarter valued at approximately $90,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.